 Dose-dense chemotherapy is one of the treatments of choice for neoadjuvant therapy in breast cancer ( BC). Activating mutations in We conducted a phase I/II study of neoadjuvant , sequential , dose-dense anthracycline/taxane chemotherapy , plus trastuzumab in HER2-positive patients and investigated the correlation of pre-treatment we established a dose-dense docetaxel recommended dose of 60 mg/m This study proposes an effective and safe neoadjuvant dose-dense anthracycline/taxane schedule and suggests that